References
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
- Faber E, Kuba A, Zapletalova J, et al. Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia. Biomedical Papers 2013;157:248–256.
- Mahon F-X, Rea D, Guilhot J, et al. on behalf of the Intergroupe Français des Leucémies Myéloïdes Chroniques (FILMC). Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
- Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122: 515–522.
- Saussele S, Richter J, Guilhot J, et al. First interim analysis of a pan-European stop trial using standardized molecular criteria: results of the EURO-SKI trial. Haematologica 2014;99(s1):792; LB2440.
- Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122:641–647.
- Breccia M, Alimena G. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leukemia Res 2013;37:713–720.
- Faber E, Friedecký D, Mičová K, et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 2012;91:923–929.
- Sanger F, Nicklen, S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463–5467.
- National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.4 http://evs.nci.nih.gov/ftp1/CTCAE/About.html
- Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789–799.
- Ohyashiki K, Katagiri S, Tauchi T, et al. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012;157:254–256.
- Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401–5411.
- Apperley JF, Szydlo RM, Gerrard G, et al. Dose interruption/reduction of tyrosine kinase inhibitors in the first 3 months of treatment of CML is associated with inferior early molecular responses and predicts for an increased likelihood of discontinuation of the 1st line agent. Blood 2013;122:2193;Abstract 632.
- Faber E, Naušová J, Jarošová M, et al. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 2006;47:1082–1090.
- Burdová K, Friedecký D, Faber E, et al. Risk perception and compliance in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Clin Therap 2013;35(Suppl.):e18.
- Faber E. Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia? Leukemia Res 2009;33:605–606.